Sternberg CN - Search Results

1

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.

Sternberg CN, Motzer RJ, Hutson TE, Choueiri TK, Kollmannsberger C, Bjarnason GA, Paul Nathan, Porta C, Grünwald V, Dezzani L, Han J, Tannir NM. Sternberg CN, et al. Clin Genitourin Cancer. 2019 Dec;17(6):425-435.e4. doi: 10.1016/j.clgc.2019.01.015. Epub 2019 Feb 6. Clin Genitourin Cancer. 2019. PMID: 31601514 Free PMC article. Clinical Trial.

2

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ. Seidman AD, et al. Among authors: sternberg cn. Cancer. 1991 Dec 15;68(12):2561-5. doi: 10.1002/1097-0142(19911215)68:12<2561::aid-cncr2820681205>3.0.co;2-g. Cancer. 1991. PMID: 1933802 Clinical Trial.

3

Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.

Sternberg CN, Yagoda A, Scher H, Bosl G, Dershaw D, Rosado K, Houston C, Rosenbluth R, Vinciguerra V, Boselli B. Sternberg CN, et al. Eur J Cancer Clin Oncol. 1989 Apr;25(4):753-4. doi: 10.1016/0277-5379(89)90215-0. Eur J Cancer Clin Oncol. 1989. PMID: 2523810 No abstract available.

4

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. Sternberg CN, et al. Cancer. 1989 Dec 15;64(12):2448-58. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. Cancer. 1989. PMID: 2819654

5

Novel agents for muscle-invasive and advanced urothelial cancer.

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. Among authors: sternberg cn. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.

6

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.

Sonpavde G, Hutson TE, Sternberg CN. Sonpavde G, et al. Among authors: sternberg cn. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. Expert Opin Investig Drugs. 2008. PMID: 18230058 Review.

7

Pazopanib for the treatment of renal cell carcinoma and other malignancies.

Sonpavde G, Hutson TE, Sternberg CN. Sonpavde G, et al. Among authors: sternberg cn. Drugs Today (Barc). 2009 Sep;45(9):651-61. Drugs Today (Barc). 2009. PMID: 19956806 Review.

8

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Sternberg CN, et al. J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100962 Clinical Trial.

9

Pazopanib: Clinical development of a potent anti-angiogenic drug.

Schutz FA, Choueiri TK, Sternberg CN. Schutz FA, et al. Among authors: sternberg cn. Crit Rev Oncol Hematol. 2011 Mar;77(3):163-71. doi: 10.1016/j.critrevonc.2010.02.012. Epub 2010 Apr 24. Crit Rev Oncol Hematol. 2011. PMID: 20456972 Review.

10

Pazopanib in renal cell carcinoma.

Sternberg CN. Sternberg CN. Clin Adv Hematol Oncol. 2010 Apr;8(4):232-3. Clin Adv Hematol Oncol. 2010. PMID: 20505644 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

469 results

Search Page

Filters